MPNST
MCID: MLG077
MIFTS: 59

Malignant Peripheral Nerve Sheath Tumor (MPNST)

Categories: Cancer diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Malignant Peripheral Nerve Sheath Tumor

MalaCards integrated aliases for Malignant Peripheral Nerve Sheath Tumor:

Name: Malignant Peripheral Nerve Sheath Tumor 12 53 59 15 73
Malignant Neurilemmoma 53 59 55
Neurofibrosarcoma 53 59 73
Mpnst 53 59 55
Malignant Neurofibroma 53 59
Malignant Schwannoma 53 59
Neurogenic Sarcoma 53 59
Malignant Neoplasm of the Peripheral Nerve Sheath 12
Malignant Peripheral Nerve Sheath Tumors 55

Characteristics:

Orphanet epidemiological data:

59
malignant peripheral nerve sheath tumor
Inheritance: Not applicable; Prevalence: 1-9/100000 (Worldwide); Age of onset: Adolescent,Adult,Childhood,Elderly,Infancy; Age of death: adolescent,adult,early childhood,elderly,infantile,late childhood,young Adult;

Classifications:

Orphanet: 59  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:5940
MeSH 44 D009442
NCIt 50 C3798
SNOMED-CT 68 19897006 77418004
Orphanet 59 ORPHA3148
UMLS via Orphanet 74 C0751690 C0206729
ICD10 via Orphanet 34 C47.9

Summaries for Malignant Peripheral Nerve Sheath Tumor

NIH Rare Diseases : 53 A malignant peripheral nerve sheath tumor (MPNST) is a tumor that develops in the protective lining that covers nerves. The first symptom of MPNST is often a lump or mass that increases in size, sometimes causing pain or a tingling sensation. MPNST is considered an aggressive tumor because there is up to a 65% chance of the tumor regrowing after surgery (a recurrence), and approximately 40% chance of spreading to distant parts of the body (a metastasis), most commonly to the lung. Treatment of MPNST begins with surgery to remove as much of the tumor as possible. Radiation therapy may be used to decrease the chance of a recurrence. Chemotherapy might be used if the whole tumor cannot be removed during surgery, or to treat a metastasis. MPNSTs are quite rare, occurring in 0.001% of the general population.  Approximately 25-50% of MPNSTs are associated with a genetic condition known as neurofibromatosis type 1.

MalaCards based summary : Malignant Peripheral Nerve Sheath Tumor, also known as malignant neurilemmoma, is related to epithelioid malignant peripheral nerve sheath tumor and malignant triton tumor. An important gene associated with Malignant Peripheral Nerve Sheath Tumor is SH3PXD2A (SH3 And PX Domains 2A), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Mechlorethamine and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include lung, bone and cervix, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 A malignant peripheral nerve sheath tumor (MPNST) (also known as "malignant schwannoma",... more...

Related Diseases for Malignant Peripheral Nerve Sheath Tumor

Diseases related to Malignant Peripheral Nerve Sheath Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 321)
# Related Disease Score Top Affiliating Genes
1 epithelioid malignant peripheral nerve sheath tumor 34.1 MUC1 NF1 S100B SMARCB1
2 malignant triton tumor 34.0 NF1 S100B
3 neurofibromatosis, type i 31.8 KIT NF1 PDGFRA
4 neurofibroma 31.3 CDKN2A KIT MUC1 NF1 NF2 PDGFRA
5 neurofibromatosis, type iv, of riccardi 31.1 KIT NF1 NF2 PDGFRA
6 perineurioma 30.6 KIT MUC1 S100B VIM
7 angiosarcoma 30.6 KIT MUC1 VIM
8 malignant spindle cell melanoma 30.6 KIT NF1 SOX10
9 sarcoma, synovial 30.5 KIT MDM2 MUC1 VIM
10 soft tissue sarcoma 30.4 EGFR MDM2 TP53
11 peritoneal mesothelioma 30.2 CDKN2A EGFR MUC1 NF2
12 neuroma 30.2 NF2 S100B SMARCB1
13 hydromyelia 30.2 S100B VIM
14 liposarcoma 30.2 CDK4 CDKN2A MDM2 TP53 VIM
15 monophasic synovial sarcoma 30.2 MUC1 S100B VIM
16 atypical neurofibroma 30.2 CDKN2A NF1 NF2 SOX10
17 neurilemmomatosis 30.2 NF1 NF2 SMARCB1
18 adenocarcinoma 30.1 CDK4 CDKN2A EGFR KIT MUC1 TP53
19 amelanotic melanoma 30.0 KIT S100B VIM
20 dedifferentiated liposarcoma 29.8 ACTC1 CDK4 CDKN2A MDM2 TP53
21 cellular schwannoma 29.7 CDKN2A MDM2 NF1 NF2 S100A1 S100B
22 glioma 29.7 CDK4 CDKN2A EGFR MDM2 NF1 PDGFRA
23 neurilemmoma 29.7 KIT NF1 NF2 PDGFRA S100B SMARCB1
24 spindle cell sarcoma 29.6 ACTC1 MDM2 MUC1 NF2 S100B VIM
25 embryonal sarcoma 29.6 CDK4 KIT MDM2 S100B TP53 VIM
26 rhabdomyosarcoma 29.5 ACTC1 CDK4 MDM2 PDGFRA TP53 VIM
27 medulloblastoma 29.5 ACTC1 CDK4 EGFR PDGFRA S100B SMARCB1
28 ewing sarcoma 29.4 CDK4 CDKN2A EGFR KIT MDM2 PDGFRA
29 leiomyosarcoma 29.3 ACTC1 CDK4 KIT MDM2 PDGFRA S100A1
30 lung cancer 29.2 CDK4 CDKN2A EGFR KIT MDM2 NRG1
31 gastrointestinal stromal tumor 29.2 ACTC1 CDKN2A EGFR KIT NF1 PDGFRA
32 ovarian cancer 29.2 CDK4 EGFR MDM2 MUC1 NRG1 TOP2A
33 malignant peripheral nerve sheath tumor with perineurial differentiation 12.6
34 neurofibrosarcoma 12.3
35 malignant glandular tumor of peripheral nerve sheath 11.8
36 melanocytic psammomatous mpnst 11.5
37 malignant melanocytic neoplasm of the peripheral nerve sheath 11.5
38 chromosome 17q11.2 deletion syndrome, 1.4-mb 11.3
39 chromosome 17q11.2 deletion syndrome 11.3
40 childhood malignant schwannoma 11.1
41 adult malignant schwannoma 11.1
42 malignant cardiac peripheral nerve sheath neoplasm 11.0
43 malignant melanocytic peripheral nerve sheath tumor of mediastinum 11.0
44 melanoma 10.6
45 sarcoma 10.6
46 ganglioneuroma 10.4
47 cauda equina neoplasm 10.4
48 plexiform neurofibroma 10.4
49 neurofibromatosis, familial spinal 10.4 NF1 NF2
50 gliofibroma 10.4 NF1 TP53

Graphical network of the top 20 diseases related to Malignant Peripheral Nerve Sheath Tumor:



Diseases related to Malignant Peripheral Nerve Sheath Tumor

Symptoms & Phenotypes for Malignant Peripheral Nerve Sheath Tumor

GenomeRNAi Phenotypes related to Malignant Peripheral Nerve Sheath Tumor according to GeneCards Suite gene sharing:

26 (show all 46)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.25 EGFR
2 Decreased viability GR00173-A 10.25 PDGFRA
3 Decreased viability GR00221-A-1 10.25 CDKN2A EGFR KIT NF1 PDGFRA SMARCB1
4 Decreased viability GR00221-A-2 10.25 NF1 SMARCB1
5 Decreased viability GR00221-A-3 10.25 CDKN2A PDGFRA SMARCB1
6 Decreased viability GR00221-A-4 10.25 CDKN2A EGFR NF1 PDGFRA
7 Decreased viability GR00301-A 10.25 KIT
8 Decreased viability GR00381-A-1 10.25 SMARCB1
9 Decreased viability GR00402-S-2 10.25 CDKN2A EGFR KIT NF1 PDGFRA SMARCB1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.02 S100B SMARCB1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-102 10.02 KIT
12 Increased shRNA abundance (Z-score > 2) GR00366-A-103 10.02 SOX10
13 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.02 VIM
14 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.02 SMARCB1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.02 CDK4 SOX10
16 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.02 EGFR
17 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.02 EGFR
18 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.02 SMARCB1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-146 10.02 VIM
20 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.02 KIT
21 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.02 KIT
22 Increased shRNA abundance (Z-score > 2) GR00366-A-170 10.02 KIT
23 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.02 SMARCB1 VIM
24 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.02 SOX10 VIM
25 Increased shRNA abundance (Z-score > 2) GR00366-A-189 10.02 VIM
26 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.02 EGFR VIM
27 Increased shRNA abundance (Z-score > 2) GR00366-A-194 10.02 SMARCB1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.02 CDK4 EGFR
29 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.02 EGFR
30 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.02 VIM
31 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.02 KIT VIM
32 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.02 SOX10
33 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.02 CDK4 KIT
34 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.02 EGFR
35 Increased shRNA abundance (Z-score > 2) GR00366-A-46 10.02 CDK4
36 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.02 SOX10
37 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.02 S100B VIM
38 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.02 SOX10
39 Increased shRNA abundance (Z-score > 2) GR00366-A-70 10.02 SOX10
40 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.02 SOX10
41 Increased shRNA abundance (Z-score > 2) GR00366-A-83 10.02 SMARCB1
42 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.02 CDK4 EGFR KIT S100B SMARCB1 SOX10
43 Increased shRNA abundance (Z-score > 2) GR00366-A-9 10.02 KIT
44 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.02 KIT
45 Decreased cell migration GR00055-A-1 9.73 CDK4 EGFR MUC1 NF1 NF2 VIM
46 Increased proliferation GR00094-A 9.13 NF2 SMARCB1 TP53

MGI Mouse Phenotypes related to Malignant Peripheral Nerve Sheath Tumor:

46 (show all 27)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.48 CDK4 CDKN2A KIT MDM2 NF1 NF2
2 cardiovascular system MP:0005385 10.47 ACTC1 CDK4 CDKN2A EGFR HTRA1 KIT
3 homeostasis/metabolism MP:0005376 10.47 ACTC1 CDK4 CDKN2A EGFR KIT MDM2
4 cellular MP:0005384 10.44 ACTC1 CDK4 CDKN2A EGFR KIT MDM2
5 growth/size/body region MP:0005378 10.44 ACTC1 CDK4 CDKN2A EGFR HTRA1 KIT
6 embryo MP:0005380 10.42 CDK4 CDKN2A EGFR KIT MDM2 NF1
7 mortality/aging MP:0010768 10.36 ACTC1 CDK4 CDKN2A EGFR KIT MDM2
8 digestive/alimentary MP:0005381 10.35 CDK4 CDKN2A EGFR KIT MDM2 NF1
9 endocrine/exocrine gland MP:0005379 10.34 CDK4 CDKN2A EGFR KIT MDM2 NF1
10 immune system MP:0005387 10.34 CDK4 CDKN2A EGFR KIT MDM2 NF1
11 hematopoietic system MP:0005397 10.32 CDK4 CDKN2A EGFR KIT MDM2 NF1
12 muscle MP:0005369 10.31 ACTC1 CDK4 CDKN2A EGFR KIT MDM2
13 integument MP:0010771 10.29 CDK4 CDKN2A EGFR KIT MDM2 NF1
14 nervous system MP:0003631 10.27 CDK4 CDKN2A EGFR KIT MDM2 NF1
15 craniofacial MP:0005382 10.22 EGFR KIT MDM2 NF1 NF2 PDGFRA
16 liver/biliary system MP:0005370 10.22 CDK4 CDKN2A EGFR KIT MDM2 NF1
17 neoplasm MP:0002006 10.22 CDK4 CDKN2A EGFR KIT MDM2 NF1
18 normal MP:0002873 10.14 ACTC1 CDK4 EGFR KIT MDM2 NF1
19 limbs/digits/tail MP:0005371 10.08 EGFR KIT MDM2 NF1 PDGFRA SOX10
20 hearing/vestibular/ear MP:0005377 10.06 EGFR KIT NF1 NF2 SH3PXD2A TP53
21 pigmentation MP:0001186 10.02 CDK4 CDKN2A EGFR KIT MDM2 NF1
22 reproductive system MP:0005389 10 CDK4 CDKN2A EGFR KIT MDM2 NF2
23 no phenotypic analysis MP:0003012 9.98 CDKN2A EGFR KIT MDM2 PDGFRA SOX10
24 renal/urinary system MP:0005367 9.97 CDK4 EGFR KIT MDM2 NF1 NF2
25 respiratory system MP:0005388 9.9 CDKN2A EGFR KIT NF1 NF2 PDGFRA
26 skeleton MP:0005390 9.65 CDKN2A EGFR HTRA1 KIT MDM2 NF1
27 vision/eye MP:0005391 9.36 CDK4 CDKN2A EGFR HTRA1 KIT NF1

Drugs & Therapeutics for Malignant Peripheral Nerve Sheath Tumor

Drugs for Malignant Peripheral Nerve Sheath Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 108)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 51-75-2 4033
2
Ifosfamide Approved Phase 3,Phase 2,Phase 1,Not Applicable 3778-73-2 3690
3
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
4
Dacarbazine Approved, Investigational Phase 3,Phase 2 4342-03-4 5351166
5
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
6
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
7
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
8
Dactinomycin Approved, Investigational Phase 3 50-76-0 457193 2019
9
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 6055-19-2, 50-18-0 2907
10
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
11
Epirubicin Approved Phase 3 56420-45-2 41867
12
Trabectedin Approved, Investigational Phase 3,Phase 2 114899-77-3 108150
13
Docetaxel Approved, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124
14
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
15
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
16
Cyproheptadine Approved Phase 3 129-03-3 2913
17
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1,Not Applicable 31703
18
Isophosphamide mustard Phase 3,Phase 2,Phase 1,Not Applicable 0
19 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
20 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable
21 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
22 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
23 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
24 Immunologic Factors Phase 3,Phase 2,Phase 1
25 Anti-Infective Agents Phase 3,Phase 2,Phase 1
26 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
27 Etoposide phosphate Phase 3,Phase 2
28 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
29 Antimitotic Agents Phase 3,Phase 2,Phase 1
30 Antirheumatic Agents Phase 3,Phase 1
31 Nucleic Acid Synthesis Inhibitors Phase 3
32 Imatinib Mesylate Phase 2, Phase 3,Phase 1 220127-57-1 123596
33 Protein Kinase Inhibitors Phase 2, Phase 3,Phase 1
34 Antiviral Agents Phase 3,Phase 2,Phase 1
35 Antimetabolites Phase 3,Phase 2,Phase 1
36 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
37 Serotonin Agents Phase 3
38 Anti-Allergic Agents Phase 3
39 Serotonin Antagonists Phase 3
40 Histamine H1 Antagonists Phase 3
41
Histamine Phosphate Phase 3 51-74-1 65513
42 Antipruritics Phase 3
43 Neurotransmitter Agents Phase 3
44 Dermatologic Agents Phase 3
45 Histamine Antagonists Phase 3
46 Gastrointestinal Agents Phase 3
47
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
48
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
49
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
50
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189

Interventional clinical trials:

(show top 50) (show all 75)
# Name Status NCT ID Phase Drugs
1 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
2 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
3 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
4 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
5 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
6 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
7 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
8 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
9 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
10 Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy Recruiting NCT01710176 Phase 3 epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3);gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8);trabectedin 1.3 mg/m2;high-dose ifosfamide 14 g/m2, given in in 14 days;etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3);gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)
11 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Active, not recruiting NCT00423618 Phase 3
12 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Suspended NCT02180867 Phase 2, Phase 3 Doxorubicin Hydrochloride;Ifosfamide;Pazopanib Hydrochloride
13 Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors Terminated NCT00427583 Phase 2, Phase 3 imatinib mesylate
14 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
15 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
16 SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors Unknown status NCT01661283 Phase 2 everolimus;bevacizumab
17 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
18 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
19 S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor Completed NCT00068367 Phase 2 erlotinib hydrochloride
20 SARC023: Ganetespib and Sirolimos in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors) Completed NCT02008877 Phase 1, Phase 2 ganetespib;Sirolimus
21 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors Completed NCT00304083 Phase 2 doxorubicin hydrochloride;etoposide;ifosfamide
22 Sorafenib and Dacarbazine in Soft Tissue Sarcoma Completed NCT00837148 Phase 2 Sorafenib and Dacarbazine
23 Trial of Dasatinib in Advanced Sarcomas Completed NCT00464620 Phase 2 Dasatinib
24 Alisertib in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01653028 Phase 2 Alisertib
25 Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma Completed NCT01614795 Phase 2 Temsirolimus
26 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
27 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2 sorafenib tosylate
28 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2 romidepsin
29 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
30 Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma Completed NCT00949325 Phase 1, Phase 2 temsirolimus (Torisel) plus liposomal doxorubicin (Doxil)
31 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2 BI 2536
32 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
33 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2 trabectedin
34 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
35 Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00041249 Phase 2 brostallicin
36 Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00041236 Phase 2 exatecan mesylate
37 Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2 perifosine
38 Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma Completed NCT00031915 Phase 2 imatinib mesylate
39 MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1 Completed NCT02096471 Phase 2 PD-0325901
40 A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery Recruiting NCT02691026 Phase 2 Pembrolizumab
41 PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors Recruiting NCT02584647 Phase 1, Phase 2 PLX3397;Sirolimus
42 A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma Recruiting NCT02601950 Phase 2 Tazemetostat
43 Hypofractionated Radiotherapy With Sequential Chemotherapy in Primary Unresectable or Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall Recruiting NCT03651375 Phase 2 Sequential chemotherapy - 3 courses of AI
44 Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers Recruiting NCT03215511 Phase 1, Phase 2 LOXO-195
45 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
46 Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Recruiting NCT02584309 Phase 2 Dexrazoxane;Doxorubicin;Olaratumab
47 Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Recruiting NCT01532687 Phase 2 Gemcitabine Hydrochloride;Pazopanib Hydrochloride
48 Autologous Dendritic Cell Vaccine Loaded With Allogeneic Tumor Lysate Expression of Cancer Testis Antigens in Patients With Soft Tissue Sarcoma Recruiting NCT01883518 Phase 1, Phase 2
49 Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma Active, not recruiting NCT02452554 Phase 2
50 Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Active, not recruiting NCT02601209 Phase 1, Phase 2 Pazopanib Hydrochloride;Sapanisertib

Search NIH Clinical Center for Malignant Peripheral Nerve Sheath Tumor

Genetic Tests for Malignant Peripheral Nerve Sheath Tumor

Anatomical Context for Malignant Peripheral Nerve Sheath Tumor

MalaCards organs/tissues related to Malignant Peripheral Nerve Sheath Tumor:

41
Lung, Bone, Cervix, Brain, Liver, Spinal Cord, Thyroid

Publications for Malignant Peripheral Nerve Sheath Tumor

Articles related to Malignant Peripheral Nerve Sheath Tumor:

(show top 50) (show all 566)
# Title Authors Year
1
Malignant peripheral nerve sheath tumor of the trigeminal nerve involving the middle and posterior cranial fossa. ( 29408426 )
2018
2
Malignant peripheral nerve sheath tumor: The need to get it right first time around. ( 29115724 )
2018
3
Malignant peripheral nerve sheath tumor of the scalp: Two rare case reports. ( 29900032 )
2018
4
Case Report: Metastasis of a Trigeminal Malignant Peripheral Nerve Sheath Tumor to the Corpus Callosum. ( 29518229 )
2018
5
Atypical presentation of a primary cardiac malignant peripheral nerve sheath tumor. ( 29318408 )
2018
6
Targeted next-generation sequencing of malignant peripheral nerve sheath tumor of the pterygopalatine fossa with intracranial metastatic recurrence. ( 29369179 )
2018
7
Case of an Intracranial Malignant Peripheral Nerve Sheath Tumor in the Setting of Pacer-dependent Heart Block. ( 29492148 )
2018
8
Immunohistochemical analysis of epigenetic factors to differentiate malignant peripheral nerve sheath tumor from benign neurofibroma in a patient with mosaic neurofibromatosis type 1: H3 lysine 27 trimethylation stain and enhancer of zeste homolog 2 stain. ( 29687471 )
2018
9
Clarifying the Distinction Between Malignant Peripheral Nerve Sheath Tumor and Dedifferentiated Liposarcoma: A Critical Reappraisal of the Diagnostic Utility of MDM2 and H3K27me3 Status. ( 29309298 )
2018
10
Extensive perineural spread of an intrapelvic sciatic malignant peripheral nerve sheath tumor: a case report. ( 29974241 )
2018
11
Low- Grade Malignant Peripheral Nerve Sheath Tumor Mimicking a Schwannoma: The Role and Importance of Trimethylated H3K27M Staining. ( 29909207 )
2018
12
Malignant Peripheral Nerve Sheath Tumor in a Patient With BAP1 Tumor Predisposition Syndrome. ( 29061454 )
2018
13
Retrobulbar malignant peripheral nerve sheath tumor in a golden retriever dog: A challenging diagnosis. ( 29606723 )
2018
14
CASE SERIES: Malignant Peripheral Nerve Sheath Tumor in the Course of the Mandibular Nerve. ( 29883816 )
2018
15
Supraclavicular Brachial Plexus Neurolysis for a Malignant Peripheral Nerve Sheath Tumor: A Case Report. ( 29894352 )
2018
16
Correction: Hypoxia-inducible factor 1 alpha is a poor prognostic factor and potential therapeutic target in malignant peripheral nerve sheath tumor. ( 29543881 )
2018
17
Tumor expression of survivin, p53, cyclin D1, osteopontin and fibronectin in predicting the response to neo-adjuvant chemotherapy in children with advanced malignant peripheral nerve sheath tumor. ( 29332262 )
2018
18
Malignant peripheral nerve sheath tumor: Transformation in a patient with neurofibromatosis type 2. ( 30408304 )
2018
19
Linear Accelerator Based Stereotactic Radiosurgery for Cranial, Intraparenchymal Metastasis of a Malignant Peripheral Nerve Sheath Tumor: Case Report and Review of the Literature. ( 30529515 )
2018
20
Malignant Peripheral Nerve Sheath Tumor of the Parotid Gland. ( 30538405 )
2018
21
Melanoma Mimicking Malignant Peripheral Nerve Sheath Tumor with Spread to the Cerebellopontine Angle: Utility of Next-Generation Sequencing in Diagnosis. ( 30050716 )
2018
22
Targeting of AKT/ERK/CTNNB1 by DAW22 as a potential therapeutic compound for malignant peripheral nerve sheath tumor. ( 30112810 )
2018
23
Cutaneous metastases of malignant peripheral nerve sheath tumor: Ineffectiveness of intralesional methotrexate. ( 30128346 )
2018
24
Malignant Peripheral Nerve Sheath Tumor Arising in Schwannomatosis with Multiple Lung Metastases. ( 30144611 )
2018
25
Malignant peripheral nerve sheath tumor originating from the adrenal gland in a dog. ( 30175755 )
2018
26
Malignant peripheral nerve sheath tumor of the thorax: Unusual location of a rare tumor. ( 30197366 )
2018
27
Malignant peripheral nerve sheath tumor of the breast in a patient with neurofibromatosis 1. ( 30230131 )
2018
28
Primary malignant peripheral nerve sheath tumor of prostate in a young adult: A case report. ( 30278486 )
2018
29
Spontaneous Transformation of Vestibular Schwannoma into Malignant Peripheral Nerve Sheath Tumor. ( 30283553 )
2018
30
BCAT1 and miR-2504: novel methylome signature distinguishes spindle/desmoplastic melanoma from superficial malignant peripheral nerve sheath tumor. ( 30310175 )
2018
31
A recurrent laryngeal nerve malignant peripheral nerve sheath tumor in a child with neurofibromatosis type 1. ( 30365627 )
2018
32
Loss of H3K27 trimethylation is not suitable for distinguishing malignant peripheral nerve sheath tumor from melanoma: a study of 387 cases including mimicking lesions. ( 28752843 )
2017
33
Fluorine-18-2-fluoro-2-deoxy-D-glucose Positron Emission Tomography/Computed Tomography Masquerading as a Case of Sporadic Malignant Peripheral Nerve Sheath Tumor of Lower Extremity Presenting as Massive Lower Limb Edema. ( 29033684 )
2017
34
Antitumor effects of 4-methylumbelliferone, a hyaluronan synthesis inhibitor, on malignant peripheral nerve sheath tumor. ( 27706810 )
2017
35
Malignant peripheral nerve sheath tumor with and without neurofibromatosis type 1. ( 28658406 )
2017
36
Radiation-Induced Glandular Malignant Peripheral Nerve Sheath Tumor. ( 28530162 )
2017
37
The Cellular Retinoic Acid Binding Protein 2 Promotes Survival of Malignant Peripheral Nerve Sheath Tumor Cells. ( 28502478 )
2017
38
Rexin-G(Ar), a tumor-targeted retrovector for malignant peripheral nerve sheath tumor: A case report. ( 28588778 )
2017
39
Malignant Peripheral Nerve Sheath Tumor of the Femur: A Rare Diagnosis Supported by Complete Immunohistochemical Loss of H3K27me3. ( 28508686 )
2017
40
Malignant Peripheral Nerve Sheath Tumor of the Inguinum and Angiosarcoma of the Scalp in a Child with Neurofibromatosis Type 1. ( 29138703 )
2017
41
Metastatic Epithelioid Malignant Peripheral Nerve Sheath Tumor in a Known Case of Neurofibromatosis-1, Cytomorphological Appearance, and Critical Analysis of Immunohistochemistry. ( 29200699 )
2017
42
Metastatic angiosarcoma arising in malignant peripheral nerve sheath tumor in a young patient with neurofibromatosis type 1. ( 28548697 )
2017
43
Role of Histone H3K27 Trimethylation Loss as a Marker for Malignant Peripheral Nerve Sheath Tumor in Fine-Needle Aspiration and Small Biopsy Specimens. ( 28898989 )
2017
44
CHD4 as a Potential Biomarker in Differentiating Between Cellular Schwannoma and Malignant Peripheral Nerve Sheath Tumor. ( 28549031 )
2017
45
Primary Intraosseous Malignant Peripheral Nerve Sheath Tumor of Metacarpal Bones of the Hand in a Patient Without Neurofibromatosis 1: Report of a Rare Case. ( 28900340 )
2017
46
Spindle cell type malignant peripheral nerve sheath tumor arising in benign schwannoma with multiple intraosseous spinal metastasis: A case report. ( 28505957 )
2017
47
Malignant peripheral nerve sheath tumor in children: A single-institute retrospective analysis. ( 29286874 )
2017
48
Hypoxia-inducible factor 1 alpha is a poor prognostic factor and potential therapeutic target in malignant peripheral nerve sheath tumor. ( 28558056 )
2017
49
Clinicopathological features and prognosis of malignant peripheral nerve sheath tumor: a retrospective study of 159 cases from 1999 to 2016. ( 29285213 )
2017
50
Acute hydrocephalus due to a primary malignant peripheral nerve sheath tumor of the cervicothoracic junction: A case report and review of the literature. ( 28502561 )
2017

Variations for Malignant Peripheral Nerve Sheath Tumor

Copy number variations for Malignant Peripheral Nerve Sheath Tumor from CNVD:

7 (show all 45)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 17387 1 142600000 147000000 Gain Malignant peripheral nerve sheath tumor
2 22132 1 165500000 170900000 Gain Malignant peripheral nerve sheath tumor
3 23047 1 170900000 176000000 Gain Malignant peripheral nerve sheath tumor
4 49109 11 102900000 112500000 Loss Malignant peripheral nerve sheath tumor
5 49995 11 112500000 121200000 Loss Malignant peripheral nerve sheath tumor
6 53584 11 31000000 36400000 Loss Malignant peripheral nerve sheath tumor
7 61507 12 1 3100000 Gain FOXM1 Malignant peripheral nerve sheath tumor
8 65742 12 21200000 26300000 Amplification SOX5 Malignant peripheral nerve sheath tumor
9 66816 12 3300000 10100000 Gain Malignant peripheral nerve sheath tumor
10 67235 12 38200000 49100000 Gain Malignant peripheral nerve sheath tumor
11 69080 12 5300000 10000000 Gain NOL1 Malignant peripheral nerve sheath tumor
12 69882 12 56428269 56432431 Gain CDK4 Malignant peripheral nerve sheath tumor
13 69960 12 56600000 71500000 Gain Malignant peripheral nerve sheath tumor
14 71535 12 71500000 86700000 Gain Malignant peripheral nerve sheath tumor
15 73254 12 92600000 109000000 Gain Malignant peripheral nerve sheath tumor
16 73259 12 92600000 96200000 Gain Malignant peripheral nerve sheath tumor
17 75380 13 19500000 25500000 Gain Malignant peripheral nerve sheath tumor
18 76637 13 34000000 55300000 Gain Malignant peripheral nerve sheath tumor
19 79536 13 73300000 77200000 Gain Malignant peripheral nerve sheath tumor
20 85488 14 47200000 67900000 Loss Malignant peripheral nerve sheath tumor
21 87451 14 73800000 107349540 Gain Malignant peripheral nerve sheath tumor
22 97234 16 1 10500000 Gain Malignant peripheral nerve sheath tumor
23 102841 16 57400000 90354753 Gain Malignant peripheral nerve sheath tumor
24 105377 16 7900000 14800000 Gain Malignant peripheral nerve sheath tumor
25 115613 17 58300000 81195210 Gain Malignant peripheral nerve sheath tumor
26 124065 19 1 13900000 Gain Malignant peripheral nerve sheath tumor
27 147242 2 61300000 68600000 Gain Malignant peripheral nerve sheath tumor
28 150135 2 96800000 114400000 Gain Malignant peripheral nerve sheath tumor
29 163892 22 32200000 44200000 Gain Malignant peripheral nerve sheath tumor
30 172609 3 184500000 198022430 Gain Malignant peripheral nerve sheath tumor
31 174546 3 2800000 16400000 Gain Malignant peripheral nerve sheath tumor
32 175421 3 39400000 54400000 Gain Malignant peripheral nerve sheath tumor
33 196162 5 159900000 180915260 Gain Malignant peripheral nerve sheath tumor
34 198008 5 18400000 23300000 Gain Malignant peripheral nerve sheath tumor
35 209673 6 27000000 57000000 Gain Malignant peripheral nerve sheath tumor
36 213890 6 52900000 70000000 Gain Malignant peripheral nerve sheath tumor
37 220382 7 13800000 43300000 Gain Malignant peripheral nerve sheath tumor
38 227906 7 72200000 86400000 Gain Malignant peripheral nerve sheath tumor
39 240607 8 52600000 146364022 Gain Malignant peripheral nerve sheath tumor
40 241476 8 6200000 36500000 Gain Malignant peripheral nerve sheath tumor
41 244863 9 1 14200000 Gain Malignant peripheral nerve sheath tumor
42 247559 9 130300000 135900000 Gain Malignant peripheral nerve sheath tumor
43 249423 9 14200000 28000000 Loss Malignant peripheral nerve sheath tumor
44 255080 9 72339785 73251640 Dramatically overexp ressed,genomicallyamplified TRPM3 Malignant peripheral nerve sheath tumor
45 255774 9 84100000 102600000 Gain Malignant peripheral nerve sheath tumor

Expression for Malignant Peripheral Nerve Sheath Tumor

Search GEO for disease gene expression data for Malignant Peripheral Nerve Sheath Tumor.

Pathways for Malignant Peripheral Nerve Sheath Tumor

Pathways related to Malignant Peripheral Nerve Sheath Tumor according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.04 EGFR KIT MDM2 MUC1 NF1 NRG1
2
Show member pathways
13.78 CDK4 CDKN2A EGFR KIT MDM2 MUC1
3
Show member pathways
13.34 EGFR KIT MUC1 NF1 NRG1 PDGFRA
4
Show member pathways
13.11 EGFR KIT MDM2 NRG1 PDGFRA TP53
5
Show member pathways
13.06 EGFR KIT MDM2 NRG1 PDGFRA TP53
6
Show member pathways
13.05 CDK4 CDKN2A EGFR MDM2 PDGFRA TP53
7
Show member pathways
12.99 CDK4 EGFR KIT MDM2 PDGFRA TP53
8
Show member pathways
12.78 CDK4 CDKN2A EGFR KIT MDM2 PDGFRA
9 12.76 EGFR KIT NF1 PDGFRA TP53
10
Show member pathways
12.74 CDK4 CDKN2A EGFR KIT SMARCB1 TP53
11 12.72 CDK4 CDKN2A EGFR KIT MDM2 PDGFRA
12
Show member pathways
12.71 EGFR KIT MDM2 NRG1 PDGFRA TP53
13
Show member pathways
12.56 CDK4 CDKN2A MDM2 TOP2A TP53
14
Show member pathways
12.52 EGFR MDM2 MUC1 NRG1 TP53
15
Show member pathways
12.43 EGFR MDM2 PDGFRA TP53
16
Show member pathways
12.41 CDK4 CDKN2A EGFR KIT
17 12.41 CDK4 CDKN2A PDGFRA TP53
18
Show member pathways
12.37 CDK4 CDKN2A MDM2 TP53
19 12.36 CDK4 CDKN2A MDM2 TP53
20 12.36 CDKN2A EGFR MDM2 PDGFRA TP53 VIM
21 12.32 CDK4 CDKN2A MDM2 TOP2A TP53 VIM
22 12.29 CDK4 MDM2 TP53 VIM
23 12.28 CDK4 CDKN2A MDM2 TP53
24
Show member pathways
12.26 EGFR KIT NRG1 PDGFRA TP53
25
Show member pathways
12.23 CDK4 CDKN2A EGFR MDM2 NF1 NRG1
26
Show member pathways
12.19 CDK4 EGFR MDM2 PDGFRA TP53
27 12.17 CDK4 CDKN2A MDM2 TP53
28 12.12 EGFR KIT NRG1 PDGFRA
29 12.08 CDK4 EGFR MDM2 PDGFRA TP53
30 12.06 CDK4 EGFR MDM2 NF1 TP53
31
Show member pathways
12.05 CDK4 EGFR NF1 NRG1
32 12 CDK4 EGFR TP53 VIM
33
Show member pathways
11.94 EGFR MDM2 NRG1 S100B
34 11.81 CDK4 MDM2 TOP2A TP53
35 11.76 PDGFRA S100B SOX10 VIM
36
Show member pathways
11.73 CDKN2A MDM2 TP53
37 11.71 CDKN2A MDM2 TOP2A TP53
38 11.62 EGFR KIT PDGFRA TP53
39 11.59 CDK4 NF1 PDGFRA
40 11.58 CDKN2A MDM2 TP53
41
Show member pathways
11.57 MDM2 TOP2A TP53
42 11.5 CDK4 MDM2 TP53
43 11.47 CDK4 MDM2 TP53
44 11.46 ACTC1 KIT NRG1 PDGFRA
45 11.42 CDK4 CDKN2A EGFR MDM2 TP53
46 11.33 CDKN2A EGFR PDGFRA TP53
47 11.32 EGFR TOP2A TP53
48 11.27 CDK4 CDKN2A EGFR MDM2 NF1 NF2
49 11.1 CDKN2A MDM2 TP53
50
Show member pathways
11.09 CDKN2A MDM2 TP53

GO Terms for Malignant Peripheral Nerve Sheath Tumor

Cellular components related to Malignant Peripheral Nerve Sheath Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleolus GO:0005730 9.86 CDK4 CDKN2A MDM2 NF1 NF2 SMARCB1
2 cytoplasm GO:0005737 9.6 ACTC1 CDK4 CDKN2A EGFR HTRA1 KIT
3 protein-containing complex GO:0032991 9.56 CDK4 EGFR MDM2 PDGFRA S100A1 SMARCB1
4 nucleus GO:0005634 10.06 CDK4 CDKN2A EGFR MDM2 MUC1 NF1

Biological processes related to Malignant Peripheral Nerve Sheath Tumor according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 viral process GO:0016032 9.99 MDM2 PDGFRA SMARCB1 TP53 VIM
2 negative regulation of cell proliferation GO:0008285 9.97 CDKN2A NF1 NF2 SMARCB1 TP53
3 peptidyl-tyrosine phosphorylation GO:0018108 9.85 EGFR KIT NRG1 PDGFRA
4 positive regulation of protein kinase B signaling GO:0051897 9.83 EGFR KIT NRG1 PDGFRA
5 negative regulation of protein kinase activity GO:0006469 9.8 CDKN2A NF1 NF2
6 MAPK cascade GO:0000165 9.8 EGFR KIT NF1 NRG1 PDGFRA
7 positive regulation of apoptotic process GO:0043065 9.8 CDK4 CDKN2A NF1 S100B TOP2A TP53
8 phosphatidylinositol phosphorylation GO:0046854 9.78 EGFR KIT NRG1 PDGFRA
9 Ras protein signal transduction GO:0007265 9.77 CDKN2A NF1 TP53
10 cellular response to drug GO:0035690 9.76 EGFR SOX10 TP53
11 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.73 MDM2 MUC1 TP53
12 wound healing GO:0042060 9.73 EGFR NF1 NRG1 PDGFRA
13 positive regulation of fibroblast proliferation GO:0048146 9.71 CDK4 EGFR PDGFRA
14 negative regulation of apoptotic process GO:0043066 9.7 ACTC1 EGFR KIT MDM2 PDGFRA SOX10
15 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.65 MUC1 TP53
16 regulation of cell proliferation GO:0042127 9.65 CDK4 EGFR KIT NF1 NF2
17 positive regulation of myelination GO:0031643 9.64 S100B SOX10
18 positive regulation of phospholipase C activity GO:0010863 9.64 KIT PDGFRA
19 replicative senescence GO:0090399 9.63 CDKN2A TP53
20 tongue development GO:0043586 9.63 EGFR KIT
21 peripheral nervous system development GO:0007422 9.63 NF1 NRG1 SOX10
22 somatic stem cell division GO:0048103 9.62 CDKN2A KIT
23 amyloid fibril formation GO:1990000 9.61 CDKN2A MDM2
24 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.61 EGFR TP53
25 obsolete negative regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle GO:0031658 9.57 CDK4 CDKN2A
26 negative regulation of cell-matrix adhesion GO:0001953 9.54 CDKN2A NF1 NF2
27 positive regulation of histone H4 acetylation GO:0090240 9.51 MUC1 SMARCB1
28 positive regulation of cell proliferation GO:0008284 9.5 CDK4 EGFR KIT MDM2 NRG1 PDGFRA
29 cellular response to actinomycin D GO:0072717 9.49 MDM2 TP53
30 positive regulation of gene expression GO:0010628 9.23 ACTC1 CDKN2A KIT MDM2 NRG1 SOX10

Molecular functions related to Malignant Peripheral Nerve Sheath Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.76 EGFR HTRA1 MDM2 S100A1 S100B SOX10
2 protein tyrosine kinase activity GO:0004713 9.71 EGFR KIT NRG1 PDGFRA
3 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.62 EGFR KIT NRG1 PDGFRA
4 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.61 EGFR KIT PDGFRA
5 disordered domain specific binding GO:0097718 9.54 CDKN2A MDM2 TP53
6 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.26 EGFR KIT NRG1 PDGFRA
7 p53 binding GO:0002039 8.92 MDM2 MUC1 SMARCB1 TP53
8 protein binding GO:0005515 10.21 CDK4 CDKN2A EGFR HTRA1 KIT MDM2

Sources for Malignant Peripheral Nerve Sheath Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....